Home » Thought Leadership » Blogs » Page 8


Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 57 posts
August 17, 2019 | Blogs

Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?

Eventual success of innovative payment models broadening access and realising the promise of cutting-edge, curative gene and cell therapies will depend on the ability of manufacturers and payers to compromise on risk sharing. Manufacturers of novel one-time treatments can increase the likelihood of successful negotiations by following a few guiding principles - CBPartners' Cell and Gene Therapy Center of Excellence analyse the future success of innovative payment models.

August 13, 2019 | Blogs

China: There’s a New NRDL in Town

Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.

CEE infographic The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes
July 10, 2019 | Blogs, Infographics

The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes

Changes to IRP policies in the CEE markets can impact pricing across the EU region and should therefore be closely monitored particularly as the list price in a given CEE market may be re-referenced by other global markets.

June 24, 2019 | Blogs

China’s IPO-Inducing Gamble

CBPartners believes that Hong Kong’s loosening of its IPO listing criteria will result in material growth for the local biotech market; however, in mainland China, infrastructural obstacles remain (e.g., insufficient industry talent) which may slow biotech development regulatory incentives. CBPartners' Asia-Pacific Center of Excellence will continue to monitor this IPO evolution.